The stock price of NLS Pharmaceutics Ltd (NASDAQ: NLSP) has jumped by 19.57 compared to previous close of 2.30. Despite this, the company has seen a gain of 24.43% in its stock price over the last five trading days. prnewswire.com reported 2025-05-21 that ZURICH, May 21, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (“CNS”) disorders, announces that it will present new preclinical data on Mazindol ER at the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (“ASCP”).
Is It Worth Investing in NLS Pharmaceutics Ltd (NASDAQ: NLSP) Right Now?
Moreover, the 36-month beta value for NLSP is 0.05. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NLSP is 2.28M and currently, short sellers hold a 1.74% of that float. On June 10, 2025, NLSP’s average trading volume was 174.68K shares.
NLSP’s Market Performance
The stock of NLS Pharmaceutics Ltd (NLSP) has seen a 24.43% increase in the past week, with a 66.67% rise in the past month, and a 61.76% gain in the past quarter. The volatility ratio for the week is 12.07%, and the volatility levels for the past 30 days are at 7.34% for NLSP. The simple moving average for the past 20 days is 39.61% for NLSP’s stock, with a -5.41% simple moving average for the past 200 days.
NLSP Trading at 63.21% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.04% of loss for the given period.
#####
#####
Stock Fundamentals for NLSP
The total capital return value is set at 0.32.
Based on NLS Pharmaceutics Ltd (NLSP), the company’s capital structure generated -0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.89. The debt to equity ratio resting at -0.18. The interest coverage ratio of the stock is -14.19.
Currently, EBITDA for the company is -11.8 million with net debt to EBITDA at -0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.69.
Conclusion
To wrap up, the performance of NLS Pharmaceutics Ltd (NLSP) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
